Share on LinkedInShare on LinkedIn

ARTICLE · 26 JANUARY 2021

Patent Appeal Board Allows Dosage Regimen Claims – No Physician Skill Needed

In the recent Commissioner's Decision Re Amgen Research (Munich) GmbH (2021 CACP 2), the Patent Appeal Board allowed medical use claims reciting a dosage

CanadaIntellectual Property

In the recent Commissioner's Decision Re Amgen Research (Munich) GmbH (2021 CACP 2), the Patent Appeal Board allowed medical use claims reciting a dosage range in Amgen's Canadian Patent Application 2,633,594 (the 594 application).

It is well known that in Canada, while methods of medical treatment are not patentable subject matter, medical use claims are considered patentable. Nevertheless, there have been several Federal Court decisions1 where a claim directed to the exercise of professional skill or judgment, for instance a claim containing a dosage range, was held to be not patentable.2 Consequently, CIPO issued the 2015 Revised Examination Practice Notice (PN 2015-01), which specified that where an essential element of a medical use claim prevents, interferes with or requires the professional skill of a physician, the claim is considered to encompass a method of medical treatment and is not patentable subject matter under s.2 of the Patent Act.  

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from